Drugs / bexmarilimab
bexmarilimab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05171062 | Jun 2023 → Dec 2025 | non-small cell lung carcinoma | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07460986 | Jul 2026 → Jul 2028 expected | soft tissue sarcoma | MedSIR | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05428969 | Jun 2022 → Mar 2027 expected | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Faron Pharmaceuticals Ltd | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05104905 | Oct 2021 → Jan 2022 | colon carcinoma, renal cell carcinoma | Faron Pharmaceuticals Ltd | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03733990 | Dec 2018 → Sep 2023 | cancer | Faron Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07672769 | Oct 2026 → Nov 2027 expected | myelodysplastic syndrome | Faron Pharmaceuticals Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bexmarilimab | “In this study, we analyzed the mode of action of a humanized IgG4 anti-Clever-1 antibody, FP-1305 (bexmarilimab), both in vitro and in patients with heavily pretreated...” PMID 34078651 ↗ Jun 2021 |
| Known as | Clevegen | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594544 ↗ |
| Known as | FP-1305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03733990 ↗ |
| Action | Inhibit | “This first-in-human trial investigates the safety and tolerability of Clever-1 blockade with bexmarilimab in patients with treatment-refractory solid tumors” PMID 38056464 ↗ Dec 2023 |
| Modality | Monoclonal antibody | “bexmarilimab, a humanized IgG4 antibody against human Clever-1” PMID 35500016 ↗ Jul 2022 |
| Route | Intravenous | “Bexmarilimab is a monoclonal antibody to common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1), administered by IV infusion every 3 weeks.” NCT05171062 ↗ |